OH-PROCTER-&-GAMBLE
11.1.2021 11:02:32 CET | Business Wire | Press release
Procter & Gamble (P&G) Oral Care seeks to advance healthy oral care habits to transform people’s health while reducing impact on the planet through its new sustainability commitments. The platform, “Healthy Smiles. Healthy Lives. Healthy Planet.”, guides its oral care brands, including Oral-B and Crest, to help unlock the lifechanging power of healthy oral care habits for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005056/en/
The World Health Organization estimates oral diseases affect 3.58 billion people, with cavities being the most prevalent issue. Both Oral-B and Crest are working to educate and enable 2 billion people to adopt healthy oral care habits by 2030, reducing their environmental footprint and enabling responsible consumption along the way.
“We are on a mission to help more people around the world understand the connection of their oral care routine to their overall health and how small changes can make a big impact,” said Alexandra Vegas, Senior Vice President Global Oral Care, P&G. “As we encourage everyone to brush twice daily for two minutes, we’ll continue to introduce products that make people want to build those healthy habits.”
Oral-B and Crest will focus their efforts on education and advocacy; enabling access to dental products and services; and innovation that makes the adoption of healthy habits enjoyable. Oral-B’s free Disney Magic Timer app, for example, is making 90% of kids brush for longer, establishing healthy brushing habits early on in childhood.
Healthy Habits for People
To drive healthy habits for people, Oral-B and Crest will improve access to oral care solutions and education to establish better oral health habits and continue to provide safe products with transparency.
During the COVID-19 pandemic, when people couldn’t visit their dentist, the brands helped protect oral health through educational articles, videos and livestreaming sessions. In the U.S., they have donated millions in product and dental care through their partnerships with Feeding America, Dental Lifeline Network and America’s Tooth Fairy. Oral-B and Crest will continue to partner with dental professionals, retailers and consumers to make progress.
Healthy Habits for the Planet
To drive healthy habits for the planet, Oral-B and Crest will encourage and enable responsible consumption by making their packaging 100% recyclable, starting with the transition to recyclable toothpaste tubes in Europe, the U.S. and Canada by 2025.
P&G Oral Care will also reduce its environmental footprint and strive for circular solutions while working with suppliers to secure transparent and responsible sourcing. Specific goals include reducing greenhouse gas emissions in operations and improving water efficiency by 35% in P&G sites by 2030.
Today P&G Oral Care factories send zero manufacturing waste to landfill globally, and all U.S. and European sites purchase 100% renewable electricity. The company has improved energy efficiency across its global Oral Care production sites by nearly 20% since 2010.
These goals are rooted in P&G's Ambition 2030 Sustainability Program, as well as three United Nations’ Sustainable Development Goals: Good Health and Wellbeing, Responsible Consumption and Production, and Reduced Inequality.
“We take a holistic approach in the way we design our oral health innovation, considering both the health of people and our planet,” said Lisa Ernst, Senior Vice President Oral Care R&D, P&G. “For example, our Oral-B electric toothbrushes help people brush better for longer and reduce oral care issues such as gum inflammation. For people who prefer to use manual toothbrushes, Oral-B Clic features replaceable toothbrush heads that reduce plastic waste by 60%.”
Visit the Oral-B website for more details on “Healthy Smiles. Healthy Lives. Healthy Planet.”
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
